APMD news

Latest 2 stories · newest Sep 8, 2026

APMD

FDA accepts NDA for Oxnimbi with PDUFA date of Feb 28, 2027

Apnimed reported second quarter 2026 financial results and is advancing commercial readiness for Oxnimbi following FDA acceptance of the NDA and completion of a successful IPO.

Regulatory Sep 8, 2026 sentiment +2.00 SEC filing ↗

APMD

Amended charter authorizes 500M shares and eliminates preferred stock series

Apnimed amended its Bylaws to authorize 500 million shares and eliminate preferred stock references as part of its IPO legal structure. Market relevance: Expands authorized share capital, signaling future financing flexibility.

Restructuring Aug 3, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same APMD feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/APMD/newsSTART FREE